Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02828020 · ClinicalTrials.gov registry record · Phase 3
Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of Migraine
A Phase 3 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,672
- Enrollment target
NCT02828020 is a Phase 3 study that has completed, run by Allergan. The registered enrollment target is 1,672 participants.
The verdict
NCT02828020, a Phase 3 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,672 participants
- Enrollment target
Study Summary
This study will evaluate the efficacy, safety, and tolerability of 2 doses of ubrogepant (50 and 100 mg) compared to placebo for the acute treatment of a single migraine attack.
Interventions
- DRUG Ubrogepant
- DRUG Placebo-matching Ubrogepant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,672 participants |
| Start Date | 2016-07-22 |
| Est. Completion | 2017-12-14 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02828020
The ClinicalTrials.gov registry entry for NCT02828020 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,672 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ubrogepant is the first listed.
NCT02828020 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02828020 about?
NCT02828020 is a clinical study titled "Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of Migraine". This study will evaluate the efficacy, safety, and tolerability of 2 doses of ubrogepant (50 and 100 mg) compared to placebo for the acute treatment of a single migraine attack.
What is the current status of trial NCT02828020?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,672 participants. The study started on 2016-07-22. Estimated completion is 2017-12-14.
What interventions are being tested in trial NCT02828020?
The interventions under investigation include: Ubrogepant (DRUG), Placebo-matching Ubrogepant (DRUG).
Who is sponsoring clinical trial NCT02828020?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.